FDA ex­perts back GSK's new malar­ia drug; Sang­amo's new­ly mint­ed CTO jumps to biotech up­start

→ Glax­o­SmithK­line has turned the fi­nal cor­ner in the race to gain an FDA ap­proval for tafeno­quine, a new treat­ment for pa­tients with P. vi­vax malar­ia. A pan­el of out­side ex­perts vot­ed 13 to 0 to en­dorse the drug and rec­om­mend an ap­proval. That comes on top of an in­ter­nal re­view that al­so backed the ap­pli­ca­tion. “If ap­proved, tafeno­quine would be the first new med­i­cine for this in­di­ca­tion in more than 60 years,” says Pauline Williams, head of Glob­al Health R&D at GSK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER